LabConnect, a premier provider of global central laboratory solutions and trial support services, has announced a strategic partnership with The Bracken Group to strengthen its radiopharmaceutical support offerings. This collaboration comes at a time when the demand for radiopharmaceutical expertise is accelerating, with industry growth projected at 15% to 20% annually, positioning LabConnect to better meet the evolving needs of pharmaceutical and biotech clients advancing targeted therapies and diagnostics.
The Bracken Group, widely regarded for its leadership in radiopharma, is known for its depth of scientific knowledge and strategic guidance. With proven expertise across development, regulatory pathways, and commercialization strategies, Bracken provides unparalleled insights that have shaped the industry. Their thought leadership and comprehensive approach bring a valuable dimension to LabConnect’s existing global capabilities.
“This collaboration represents a powerful opportunity to bring together operational excellence and scientific depth,” said Wes Wheeler, Chief Executive Officer of LabConnect. “We can increase our capacity to assist international clients in overcoming the particular analytical and logistical difficulties present in radiopharmaceutical trials by integrating Bracken’s experience in the field.”
Colin Miller, PhD, Chief Executive Officer of Bracken Consulting, added, “LabConnect’s innovative culture aligns with our mission at Bracken. Together, we are creating an unmatched bridge that connects medicine, science, and operations. As the leading consultancy in radiopharmaceutical development—from pre-clinical through market strategy—this partnership enables us to enhance LabConnect’s positioning as a trusted partner for clients pursuing radiopharmaceutical diagnostics and radiolabeled therapies (RLT).”
Through this collaboration, the two organizations will expand service delivery in key areas such as sample processing, logistics management, and scientific oversight, all of which are crucial in the highly complex and regulated radiopharmaceutical space. By combining LabConnect’s global operational reach with Bracken’s specialized knowledge, the partnership aims to deliver comprehensive solutions that accelerate innovation and support the development of next-generation treatments worldwide.
